Prediction of serious complications in patients with seemingly stable febrile neutropenia : validation of the Clinical Index of Stable Febrile Neutropenia in a prospective cohort of patients from the FINITE study
© 2015 by American Society of Clinical Oncology..
PURPOSE: To validate a prognostic score predicting major complications in patients with solid tumors and seemingly stable episodes of febrile neutropenia (FN). The definition of clinical stability implies the absence of organ dysfunction, abnormalities in vital signs, and major infections.
PATIENTS AND METHODS: We developed the Clinical Index of Stable Febrile Neutropenia (CISNE), with six explanatory variables associated with serious complications: Eastern Cooperative Oncology Group performance status ≥ 2 (2 points), chronic obstructive pulmonary disease (1 point), chronic cardiovascular disease (1 point), mucositis of grade ≥ 2 (National Cancer Institute Common Toxicity Criteria; 1 point), monocytes < 200 per μL (1 point), and stress-induced hyperglycemia (2 points). We integrated these factors into a score ranging from 0 to 8, which classifies patients into three prognostic classes: low (0 points), intermediate (1 to 2 points), and high risk (≥ 3 points). We present a multicenter validation of CISNE.
RESULTS: We prospectively recruited 1,133 patients with seemingly stable FN from 25 hospitals. Complication rates in the training and validation subsets, respectively, were 1.1% and 1.1% in low-, 6.1% and 6.2% in intermediate-, and 32.5% and 36% in high-risk patients; mortality rates within each class were 0% in low-, 1.6% and 0% in intermediate-, and 4.3% and 3.1% in high-risk patients. Areas under the receiver operating characteristic curves in the validation subset were 0.652 (95% CI, 0.598 to 0.703) for Talcott, 0.721 (95% CI, 0.669 to 0.768) for Multinational Association for Supportive Care in Cancer (MASCC), and 0.868 (95% CI, 0.827 to 0.903) for CISNE (P = .002 for comparison between CISNE and MASCC).
CONCLUSION: CISNE is a valid model for accurately classifying patients with cancer with seemingly stable FN episodes.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2015 |
|---|---|
| Erschienen: |
2015 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:33 |
|---|---|
| Enthalten in: |
Journal of clinical oncology : official journal of the American Society of Clinical Oncology - 33(2015), 5 vom: 10. Feb., Seite 465-71 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Carmona-Bayonas, Alberto [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Antineoplastic Agents |
|---|
| Anmerkungen: |
Date Completed 20.04.2015 Date Revised 10.12.2019 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1200/JCO.2014.57.2347 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM245067426 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM245067426 | ||
| 003 | DE-627 | ||
| 005 | 20231224140049.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231224s2015 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1200/JCO.2014.57.2347 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0816.xml |
| 035 | |a (DE-627)NLM245067426 | ||
| 035 | |a (NLM)25559804 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Carmona-Bayonas, Alberto |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Prediction of serious complications in patients with seemingly stable febrile neutropenia |b validation of the Clinical Index of Stable Febrile Neutropenia in a prospective cohort of patients from the FINITE study |
| 264 | 1 | |c 2015 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 20.04.2015 | ||
| 500 | |a Date Revised 10.12.2019 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2015 by American Society of Clinical Oncology. | ||
| 520 | |a PURPOSE: To validate a prognostic score predicting major complications in patients with solid tumors and seemingly stable episodes of febrile neutropenia (FN). The definition of clinical stability implies the absence of organ dysfunction, abnormalities in vital signs, and major infections | ||
| 520 | |a PATIENTS AND METHODS: We developed the Clinical Index of Stable Febrile Neutropenia (CISNE), with six explanatory variables associated with serious complications: Eastern Cooperative Oncology Group performance status ≥ 2 (2 points), chronic obstructive pulmonary disease (1 point), chronic cardiovascular disease (1 point), mucositis of grade ≥ 2 (National Cancer Institute Common Toxicity Criteria; 1 point), monocytes < 200 per μL (1 point), and stress-induced hyperglycemia (2 points). We integrated these factors into a score ranging from 0 to 8, which classifies patients into three prognostic classes: low (0 points), intermediate (1 to 2 points), and high risk (≥ 3 points). We present a multicenter validation of CISNE | ||
| 520 | |a RESULTS: We prospectively recruited 1,133 patients with seemingly stable FN from 25 hospitals. Complication rates in the training and validation subsets, respectively, were 1.1% and 1.1% in low-, 6.1% and 6.2% in intermediate-, and 32.5% and 36% in high-risk patients; mortality rates within each class were 0% in low-, 1.6% and 0% in intermediate-, and 4.3% and 3.1% in high-risk patients. Areas under the receiver operating characteristic curves in the validation subset were 0.652 (95% CI, 0.598 to 0.703) for Talcott, 0.721 (95% CI, 0.669 to 0.768) for Multinational Association for Supportive Care in Cancer (MASCC), and 0.868 (95% CI, 0.827 to 0.903) for CISNE (P = .002 for comparison between CISNE and MASCC) | ||
| 520 | |a CONCLUSION: CISNE is a valid model for accurately classifying patients with cancer with seemingly stable FN episodes | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Multicenter Study | |
| 650 | 4 | |a Validation Study | |
| 650 | 7 | |a Antineoplastic Agents |2 NLM | |
| 700 | 1 | |a Jiménez-Fonseca, Paula |e verfasserin |4 aut | |
| 700 | 1 | |a Virizuela Echaburu, Juan |e verfasserin |4 aut | |
| 700 | 1 | |a Antonio, Maite |e verfasserin |4 aut | |
| 700 | 1 | |a Font, Carme |e verfasserin |4 aut | |
| 700 | 1 | |a Biosca, Mercè |e verfasserin |4 aut | |
| 700 | 1 | |a Ramchandani, Avinash |e verfasserin |4 aut | |
| 700 | 1 | |a Martínez, Jerónimo |e verfasserin |4 aut | |
| 700 | 1 | |a Hernando Cubero, Jorge |e verfasserin |4 aut | |
| 700 | 1 | |a Espinosa, Javier |e verfasserin |4 aut | |
| 700 | 1 | |a Martínez de Castro, Eva |e verfasserin |4 aut | |
| 700 | 1 | |a Ghanem, Ismael |e verfasserin |4 aut | |
| 700 | 1 | |a Beato, Carmen |e verfasserin |4 aut | |
| 700 | 1 | |a Blasco, Ana |e verfasserin |4 aut | |
| 700 | 1 | |a Garrido, Marcelo |e verfasserin |4 aut | |
| 700 | 1 | |a Bonilla, Yaiza |e verfasserin |4 aut | |
| 700 | 1 | |a Mondéjar, Rebeca |e verfasserin |4 aut | |
| 700 | 1 | |a Arcusa Lanza, María Ángeles |e verfasserin |4 aut | |
| 700 | 1 | |a Aragón Manrique, Isabel |e verfasserin |4 aut | |
| 700 | 1 | |a Manzano, Aránzazu |e verfasserin |4 aut | |
| 700 | 1 | |a Sevillano, Elena |e verfasserin |4 aut | |
| 700 | 1 | |a Castañón, Eduardo |e verfasserin |4 aut | |
| 700 | 1 | |a Cardona, Mercé |e verfasserin |4 aut | |
| 700 | 1 | |a Gallardo Martín, Elena |e verfasserin |4 aut | |
| 700 | 1 | |a Pérez Armillas, Quionia |e verfasserin |4 aut | |
| 700 | 1 | |a Sánchez Lasheras, Fernando |e verfasserin |4 aut | |
| 700 | 1 | |a Ayala de la Peña, Francisco |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of clinical oncology : official journal of the American Society of Clinical Oncology |d 1986 |g 33(2015), 5 vom: 10. Feb., Seite 465-71 |w (DE-627)NLM012608777 |x 1527-7755 |7 nnns |
| 773 | 1 | 8 | |g volume:33 |g year:2015 |g number:5 |g day:10 |g month:02 |g pages:465-71 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1200/JCO.2014.57.2347 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 33 |j 2015 |e 5 |b 10 |c 02 |h 465-71 | ||